ArticleProceedings of the National Academy of Sciences of the United States of America2022

Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I

Natalie K Wolf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.